DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report)'s stock had its "buy" rating reissued by investment analysts at HC Wainwright in a report released on Thursday,Benzinga reports. They currently have a $10.00 target price on the stock. HC Wainwright's target price would suggest a potential upside of 143.90% from the stock's current price.
DiaMedica Therapeutics Stock Performance
Shares of DMAC stock traded down $0.09 during trading hours on Thursday, hitting $4.10. 89,854 shares of the company were exchanged, compared to its average volume of 81,863. The firm has a market cap of $175.82 million, a P/E ratio of -7.32 and a beta of 1.29. DiaMedica Therapeutics has a fifty-two week low of $2.14 and a fifty-two week high of $6.82. The company has a 50 day simple moving average of $3.89 and a two-hundred day simple moving average of $4.98.
DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.18) EPS for the quarter, hitting the consensus estimate of ($0.18). During the same quarter last year, the company posted ($0.14) EPS. As a group, sell-side analysts expect that DiaMedica Therapeutics will post -0.59 EPS for the current fiscal year.
Institutional Trading of DiaMedica Therapeutics
Hedge funds have recently bought and sold shares of the business. Balyasny Asset Management L.P. acquired a new stake in DiaMedica Therapeutics in the 4th quarter valued at $79,000. Y Intercept Hong Kong Ltd acquired a new stake in DiaMedica Therapeutics in the 4th quarter valued at $81,000. Raymond James Financial Inc. bought a new position in DiaMedica Therapeutics during the 4th quarter valued at $83,000. Bank of Montreal Can bought a new position in DiaMedica Therapeutics during the 4th quarter valued at $84,000. Finally, Cornerstone Wealth Management LLC bought a new position in DiaMedica Therapeutics during the 1st quarter valued at $62,000. Institutional investors and hedge funds own 10.12% of the company's stock.
DiaMedica Therapeutics Company Profile
(
Get Free Report)
DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.
Recommended Stories
Before you consider DiaMedica Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DiaMedica Therapeutics wasn't on the list.
While DiaMedica Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
